Plant Medicine Podcast

In this episode of the Psychedelic Medicine Podcast, East Forest joins to discuss several aspects at the intersection of music and psychedelics, including how he created the music that so many have used when facilitating psychedelic journeys. East Forest’s latest project, a feature length documentary film called Music For Mushrooms, follows him through the psychedelic renaissance on a mission to pair music with psychedelics to bring about transformative healing to a world in crisis.

In this conversation, East Forest discusses how he first got started making music for psychedelic journeys and the considerations that go into curating the right sound to best support these types of deep inner experiences. He emphasizes the importance of avoiding music that sounds overly sentimental and lacks the depth and richness important for effective psychedelic exploration. He also discusses the importance of maintaining the container, whether in the context of psychedelic facilitation or purely music-focused ceremonies, and suggested that sternness and fortitude have an important function in this context. In closing, East Forest suggests that music is so powerful because of the way it is able to be a point of connection to integrate experiences and bring people together.

In this episode you'll hear:

• Composing soundtracks for psychedelic journeys with different substances

• Integrating nature sounds into compositions

• Flow states and music

• Bringing live elements of music and sound into a psychedelic ceremony

• Singing as a regulating technique during a psychedelic journey

• The intersection of music, technology, and psychedelics

Quotes:

“If we look at psychedelic experiences and ceremonies from indigenous use, all of them that I know of were guided by music.” [3:16]

“I think it’s more the intention behind the music. I don’t think there’s a particular thing you have to do or not do, but I don’t think you can just play any music. So I think it’s the intention of the music and the intention of the room and the intention of the participants… There has to be an invitation on all of those fronts for that doorway to open.” [16:11]

“I think we’re looking for music and for space that is supportive of that through-line and gives us enough time to be in a process—and that’s another advantage of having these longform, intentional, bespoke songs because they are probably going to give more of that time and space for these processes to occur.” [32:43]

Links:

East Forest’s website

East Forest on Instagram

East Forest on Tik Tok

Music for Mushrooms documentary website

Music for Mushrooms Official Documentary Soundtrack

Winter Solstice Retreat at Esalen

Music for Psychedelic Therapy by Jon Hopkins

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Eric Sienknecht, PsyD joins to discuss the roles of music in psychedelic sessions. Dr. Sienknecht is a licensed clinical psychologist and co-founder and lead trainer at Polaris Insight Center, a ketamine-assisted psychotherapy clinic and training center. He has worked as sub-investigator and study therapist on the Lykos-sponsored MDMA-AT clinical trials for PTSD and currently is also a supervisor and educator in MDMA-AT for various clinical trial sites. Dr. Sienknecht has a deep interest in the role and use of music in ketamine and MDMA sessions and specializes in curating playlists for psychedelic experiences.

In this conversation, Dr. Sienknecht discusses how he first realized the importance of music in psychedelic experiences. He shares insights on how different genres and moods of music may be better suited to certain phases of the psychedelic experience and how he works individually with clients to better tailor a session playlist to their personal taste. Dr. Sienknecht even discusses how to strategically include shadow elements in a playlist to facilitate a client going deeper in their journey. In closing, he emphasizes how the intersection of psychedelic experiences and music remains understudied with only a few book chapters and articles dealing directly with the topic, so there is much yet to learn and explore in this exciting niche. 

In this episode you'll hear:

• What is universal vs what is individual when it comes to music and psychedelics

• Why Dr. Sienknecht avoids music with lyrics in a participant’s native language for psychedelic sessions

• The research on different genres of music for psychedelic journeys

• Balancing planning music in advance and adapting to the specific pace and mood of the client’s experience

• Utilizing nature sounds alongside or within music during psychedelic sessions

• Binaural beats and brainwaves

Quotes:

“There’s generally better tracks to use for the opening phase of a [psychedelic] journey, for the peak phase of a journey [etc], and there’s been some research into that as well.” [6:05]

“Taste is so subjective… Knowing your client and talking with them beforehand about their taste and letting that information really inform how you create the playlist is really important.” [27:02]

“One of the benefits of doing psychedelic therapy is that you can surrender control over elements of set and setting—not that those aren’t negotiable and ongoingly negotiable, as they should be—but there’s something about [the fact that the therapist] has got the music taken care of, the room set up, everything is in its right place. All I have to do is fast from food for a few hours, have my intention, and step into the journey—and that can help someone to really just trust and surrender more into the experience.” [30:20]

Links:

Integral Psychedelic Therapy edited by Jason A. Butler, Genesee Herzberg, and Richard Louis Miller

Dr. Sienknecht on LinkedIn

Polaris Insight Center on LinkedIn

Polaris Insight Center website

Music for Ketamine-Assisted Psychotherapy Sessions training with Dr. Sienknecht at Polaris Insight Center

Previous episodes: Psychedelics and Nature: The Symbiotic Relationship with Dr. Sam Gandy

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Giorgia Caspani, PhD joins to discuss the intersection of psychedelics and the gut microbiome and ramifications for future personalized medicine. Dr. Caspani is a neuroscientist and computational biologist working at the intersection of gut microbiome, psychedelics and personalized medicine.

In this conversation, Dr. Caspani discusses her research published in the article “Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis.” She shares what we know about how psychedelics impact the gut microbiome from initial studies and what questions remain unanswered. She draws connections between the way the gut microbiome metabolizes SSRI drugs and how serotonin impacts the gut microbiota to hypothesize the potential ways psychedelics interact with this complex living system. In closing, Dr. Caspani discusses the possibility of predicting responses to psychedelic treatments using data from the microbiota, and the research currently happening to make this possible. 

In this episode you'll hear:

• How human beings and our gut microbiome co-evolved and the benefits achieved through this symbiotic relationship

• The correlation between the gut microbiome and stress levels 

• The effects of psychedelics on immune responses

• Why personalized medicine may be a more effective approach for treating depression

• How personalized medicine could help make psychedelic therapies more accessible and effective

Quotes:

“Without our gut microbes… We wouldn't be able to really perform a lot of the metabolic functions that we rely on as humans.” [4:26]

“The gut microbiome is different in every person—it’s very unique. And so every person carries this unique microbial signature that can potentially map out to all of the treatment options that we already have available; it’s just a matter of understanding and identifying markers that can predict which patient will benefit from a specific drug.” [18:22]

“[We hypothesize that] the gut microbiome shapes individual responses to psychedelic treatment. And so if that [hypothesis] is correct, if that is true, we could potentially target the microbiome, change the composition of the gut microbiome like we wanted to, to be able to maximize the effectiveness of these [psychedelic] drugs.” [25:14]

Links:

Dr. Caspani’s article, “Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis”

Dr. Caspani on LinkedIn

Dr. Caspani on X

Onaya Science website

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Star Rose Bond, LCSW joins to discuss the topic of using psychedelic-assisted therapy to address intergenerational trauma. As seen in Huffpost, Vice and Psychology Today, Star Rose is a Renegade Psychotherapist, Social Activist, Clinical Supervisor for PEARL Institute and Co-Founder of Life Camp. With a Bachelor’s degree from NYU and a master’s from Columbia, Star brings 15 years of clinical trauma therapeutic services and experience serving marginalized, under-resourced and at risk populations specializing in harm reduction and PTSD recovery.

In this conversation, Star introduces the topic of intergenerational trauma and explores how psychedelic experiences may be leveraged to address this pernicious condition. She begins by explaining what intergenerational trauma means, how it gets passed down, and how it manifests. Star talks about the importance of psychedelic therapists and facilitators having awareness of trauma-informed modalities in order to better serve these populations. She also discusses the complexities of addressing generational trauma, and how it can often be difficult to process sensitive topics within the family unit. However, in conclusion, Star emphasizes that the capacity to heal is an intrinsic aspect of human existence, and that even in particularly dark moments, it is possible to get in touch with this possibility. 

In this episode you'll hear:

• How the conditions of Capitalism produce and exacerbate chronic stress

• The profound impact of neglect and abuse in early childhood 

• The unique experience of intergenerational trauma for BIPOC peoples and the recent rekindling of a spirit of connection in these communities due to psychedelic medicines 

• How processing intergenerational trauma can transform familial relationships

• Ethical and practical considerations for facilitators and therapists guiding clients through psychedelic experiences aimed at resolving deep-seated trauma

• What to look for in a psychedelic-assisted therapist or facilitator

Quotes:

“Just because you have several students or several clients who’ve experienced the same trauma, don’t make the assumption that they’re all experiencing it the same way. Or maybe you’ll meet a client who has had trauma similar to yours—don’t assume that they have undergone the same emotional impact or psychological impact as you. The truth of the matter is we are complex beings. We have so many different moving variables that go into our psychology and that essentially indicate or play a role in how we respond to things.” [8:43]

“We can’t always express or understand why things happen the way they do. But, we can start to make meaning through a spiritual understanding which in turn lends itself to a sense of ease and comfort.” [22:20]

“When you are going into these experiences as a facilitator—whatever your background is—it is of the utmost importance that you are hyper cognizant and hyper aware of the harms that can be caused by not being aware of the ways in which you can navigate someone else’s trauma as it shows up.”  [25:02]

Links:

Star’s website

Star on Instagram

Previous episode: Can Your Genes Predict Response to MDMA Therapy? with Dr. Dave Rabin MD, PhD

Previous episode: Warning Signs When Selecting a Psychedelic Facilitator with Juliana Mulligan

Previous episode: How to Choose a Psychedelic Facilitator or Retreat Center with Joël Brierre

My Grandmother's Hands: Racialized Trauma and the Pathway to Mending Our Hearts and Bodies by Resmaa Menakem

SHINE Support website

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, L.J. Lumpkin III, MA LMFT joins to discuss the potential of psychedelic medicine in the context of sports psychology. L.J. is a therapist, adjunct professor at Pepperdine University, a coach, author, speaker, and the CEO of Nomad Healing Practices.

In this conversation, L.J. shares his personal experience as an athlete and discusses the difficult transition to a new life once an athlete’s career has concluded. He compares the need to reinvent oneself in this context to ego death and explains how psychedelic-assisted therapy may be helpful for navigating this transition. L.J. also discusses the intense pressure athletes are under to perform, mentioning that the drive to win can often overpower the more basic mode of play at the heart of athleticism. This is an area where he finds ketamine to be a particularly powerful medicine, as its dissociate quality can help athletes tune out the high pressure expectations. L.J. also discusses leveraging the critical learning period provided by psychedelic therapies to institute new healthy habits, something which could benefit athletes both on and off the field. 

In this episode you'll hear:

• How ketamine-assisted therapy may be able to help athletes with their unique psychological challenges

• Integrating mindfulness to prepare for psychedelic therapies

• Leveraging the somatic component of psychedelic therapies to address pain

• The importance of integration practices and support systems

• The differences between working with psilocybin versus ketamine

• Drowning out critics and sports commentary and getting back to basics with the help of psychedelic therapy

Quotes:

“If you’ve been paid millions of dollars to hit and be aggressive for so long and that’s how you’ve dealt with your emotions—and it wasn’t a problem because you were being rewarded for it—what do you do when you’re not getting rewarded for that anymore? When you have to actually change how you process emotion—there’s not a playbook for that.” [7:46]

“Just talking about [mental health] and normalizing it—all of a sudden you’re allowed to get help, you’re allowed to heal, you’re allowed to go to practices that have been practiced throughout human civilization. We’re bringing [psychedelics] back and I think that athletes are the ones who are really going to be the ship of normalization.” [22:38]

“Especially if you’re off season, those other medicines [besides ketamine] I think they’re going to be even more helpful because that might encourage the rest, it might encourage being able to connect with family systems. I think for some of the more acute stuff, the ketamine does serve a great purpose in that.” [28:16]

Links:

L.J. on Instagram

L.J. on LinkedIn

Nomad Healing Practices website 

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, podcast host Dr. Lynn Marie Morski comes on the mic to provide a five-year update on the podcast and share the changes in the legal landscape of psychedelics in the past half-decade. Lynn Marie Morski, MD, JD is the president of the Psychedelic Medicine Association and host of the Psychedelic Medicine Podcast. She sits on the advisory boards of Psychedelics Today, Cybin, VETS, Inc (Veterans Exploring Treatment Solutions), the Oxenberg Foundation, and the Ketamine Task Force. Dr. Morski is a Mayo Clinic-trained physician in family medicine and sports medicine, as well as an attorney and former adjunct law professor.

In this anniversary episode you’ll hear about the legally-accessible forms of psychedelic therapy which have come to prominence as potential mainstream therapeutics in recent years. Dr. Mroski shares Information on the legal adult use framework for psilocybin in Oregon, including licensing, costs, and exclusion criteria. She also discusses programs in Australia and Canada that will allow certain patients to access psychedelic therapies such as psilocybin- and MDMA-assisted therapy. In addition to classic psychedelic medicines, Dr. Morski also shares information on the medicine which is currently most accessible: ketamine. She discusses the difference between S-ketamine and R-ketamine and on-label and off-label uses of this substance. In closing, Dr. Morski presents some of the finer details of the current landscape of insurance coverage for ketamine. 

In this episode you'll hear:

• The difference between decriminalization and legalization

• The FDA decision to deny the Lykos Therapeutics’ new drug application for MDMA-assisted therapy for PTSD

• The upcoming Colorado psilocybin program

• Psychiatric licenses to administer MDMA and LSD to patients in Australia 

• The Special Access Program for psychedelic therapies in Canada 

• Legal ketamine access in the United States

• How the Psychedelic Medicine Podcast chooses guests

Quotes:

“I wanted to focus mostly on what is legal because we know that’s the way things are going to be the most monitored and therefore safely accessible.” [20:45]

“People are in this industry because they want other people to feel better and they want to help and they’re so generous with their time” [25:31]

Links:
clinicaltrials.gov - the place to find information on upcoming clinical trials for psychedelic medicine for which you may qualify

Insurance Coverage for Psychedelic Therapy by Vincent Joralemon

SPRAVATO withMe Patient Support Program

Enthea insurance

Previous episode: How to Choose A Psychedelic Facilitator or Retreat Center with Joël Brierre

Previous episode: Warning Signs When Selecting a Psychedelic Facilitator with Juliana Mulligan

Previous episode: Ketamine Scientific Research with Dr. Jason Wallach

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Dr. David Rabin, MD, PhD joins to discuss whether genes can be predictive of one’s response to MDMA Therapy. Dr. Rabin, a board-certified psychiatrist and neuroscientist, is the co-founder & chief medical officer at Apollo Neuroscience. In addition to his clinical psychiatry practice, Dr. Rabin is also the co-founder & executive director of The Board of Medicine, and a psychedelic clinical researcher currently evaluating the mechanism of psychedelic-assisted psychotherapy in treatment-resistant mental illnesses.

In this conversation, Dr. Rabin shares his research into epigenetic responses to MDMA-therapy, exploring topics of trauma, gene expression, and personalized, data-driven medicine. He discusses the seminal discovery that trauma can cause epigenetic changes in the structure and function of the cortical system and his own research findings that uncovered a reversal of these changes associated with MDMA-assisted therapy. Dr. Rabin hopes further research in this area may allow for leveraging epigenetic data to determine which psychedelic medicine a particular patient may be most likely to respond to and track how effective a given treatment has been. In closing, he expresses excitement about bringing objective biological precision to mental health treatment, drawing a parallel to the discovery of antibiotics which allowed for much more tailored treatments of infections which has saved countless lives. 

In this episode you'll hear:

• Response rates to psychedelic-assisted therapy for PTSD versus conventional therapies

• The consequences of ineffective treatment for PTSD

• MDMA-assisted therapy as preventative care and the societal cost savings involved

• Genetics, epigenetics, and gene expression

• Using epigenetic data from simple saliva swabs to better gauge response to MDMA-assisted therapy for PTSD

Quotes:

“Most of the treatments we have available today for PTSD—that are the FDA-cleared, considered gold standard treatments—only actually induce remission from illness… in about 30% of people. So of the 100% of the millions of people every year that are getting treated for PTSD, with the best treatments that we have that are currently available, only 30%—at best—are getting better long term. Everyone else has a diagnosis of PTSD for life.”  [3:55]

“MDMA-assisted therapy for people with PTSD is having an effect that’s similar to what we saw with the discovery of antibiotics for infection.” [8:07]

“Folks with severe PTSD who went through this trial, when they received MDMA-assisted therapy, [the researchers] saw a statistically significant change—in terms of repair—of the cortisol receptor’s epigenetic code which reflects improved structure and function of that receptor site. But not only that—we saw that the amount that people got better… was directly correlated with… the amount of remodeling and repair at the receptor site.” [18:36]

“Epigenetic code is actually something that can be modified by experiences in our environment. And trauma—or PTSD diagnoses, a series of significant traumas over time—can in fact change epigenetic code of the cortisol receptor gene. And that changes how the cortisol receptor gene gets made, and it changes its function.”  [29:52]

“PTSD is a disorder of learned fear. How do we treat PTSD? In animals and humans, we provide the same stimulation that they were getting that they are now afraid of in the context of safety. That’s how exposure therapy works, that’s how MDMA therapy works to some extent—all of these tools and techniques work to treat PTSD effectively… in the same way. It’s called safety conditioning.” [36:48]

Links:

Dr. Rabin’s article: Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD

Dr. Rabin’s website

Dr. Rabin on LinkedIn

Dr. Rabin on Instagram 

Dr. Rabin on Twitter 

Apollo Neuroscience website 

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Mark Braunstein, DO joins to discuss the promise and the peril of ketamine. Dr. Braunstein graduated medical school in 1997 then completed a General Psychiatry Residency at the University of New Mexico and then a fellowship in Child and Adolescent psychiatry at Maine Medical Center in 2002. Upon graduation from his fellowship and becoming board certified in general psychiatry he established a private practice in Durango, Colorado where plant medicine became part of his everyday integrative psychiatric practice. 

In this conversation, Dr. Braunstein shares some of the developments in the world of ketamine in the past three years since his previous episode, drawing on his own experience providing ketamine-assisted therapies. He stresses issues of grandiosity that can arise both when working with ketamine and when taking the medicine—issues which in the worst case and fuel ketamine use disorders. Dr. Braunstein stresses the importance of clinicians providing ketamine treatments being realistic and upfront about the potential harms of ketamine when advising prospective patients. In closing, he warns against the dangers of being in an echo chamber which reinforces potentially pathological substance use, especially for clinicians in the ketamine space. 

In this episode you'll hear:

• Why ketamine has an addictive potential and how ketamine addiction presents

• Ways to treat ketamine use disorder 

• The importance of informed consent

• What patients should look for when seeking a ketamine provider

• The importance of ketamine providers working with multiple modalities and having multiple tools in the toolbox besides ketamine 

Quotes:

“Here’s what’s scary to me about ketamine: these people that I’ve seen having problems [with ketamine use] are largely lifetime recreational psychedelic/drug users without problems. And these are people who have made it to age fifty, smoking [cannabis], tripping a little bit, their whole life without having a problem—then at fifty years old, find themselves hooked on something for the first time.” [12:30]

“[Ketamine] is not a microdosing medication… There is no such thing as ketamine microdosing. You think of microdosing as sub-perceptual. Everyone that I’ve met that’s abusing ketamine, it was not a sub-perceptual effect—they were very much abusing it to have that perceived effect. Maybe not a psychedelic effect—usually an intoxicated wonky effect is what they’re going for. And people refer to that as microdosing. It’s not microdosing. It’s abusing small doses.” [17:11]

“What do I see that makes me concerned with someone I’m talking to—a clinician or a client? That grandiosity. So that gets me concerned right away when I hear about these ‘downloads’ because that’s where … other psychedelics can have dependency too. You see people … they go for aya ceremonies every week after week after week. So there can be an addiction to the download or to the release.” [34:35]

“The people I know that have been successful in this line of work (from a patient standpoint), whether they’re a clinician or not, have been the ones that have embraced the work. And just knowing that this is going to be a process and I’m in it to win it, for life. I’m working on myself.”  [35:40]

Links:

Dr. Braunstein on LinkedIn

Ketamine Research Foundation website

NeuPath Mind Wellness website 

Ketamine Training Center website

Previous episode: Ketamine for Alcohol Use Disorder with Steven Mandel, MD

Previous episode: Avoiding the Traps of Psychedelic Self-Absorption with Adam Aronovich, PhD(c)

Previous episode: Navigating Psychedelic Narcissism with Adam Aronovich

Previous episode: Psychedelic Therapy: Slow Down to Heal Faster with Sunny Strasburg, LMFT 

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Steve Rio joins to discuss 5-MeO-DMT for Trauma and PTSD. Steve is a psychedelic facilitator and Co-Founder of Enfold, which offers a groundbreaking psychospiritual model that combines psychedelic intensives, coaching, and community to help individuals heal trauma and reach their full potential. 

In this conversation, Steve shares his journey of how he got into facilitating 5-MeO-DMT experiences and insights on working safely and effectively with this medicine over the course of his practice. He discusses the screening procedure he uses before clearing clients for facilitated 5-MeO-DMT experiences to ensure safety as much as possible when working with this powerful psychedelic. Steve also talks about how he tailors his work with clients based on the state of their nervous system and their unique personality. In closing, Steve emphasizes the somatic quality of 5-MeO-DMT experiences, sharing different types of experiences people typically have on the medicine and how these can best be integrated.

In this episode you'll hear:

• Preparation for safe and effective 5-MeO-DMT experiences

• Stories of transformation following 5-MeO-DMT healing for PTSD and focused integration practices

• How common 5-MeO-DMT reactivations are, and when they typically happen

• Issues of spiritual bypassing in underground psychedelic facilitation

• How to navigate informed consent in the context of facilitating psychedelic experiences

Quotes:

“At the peak of the 5-MeO experience, there is no mind… When people talk about the death and the rebirth experience with 5-MeO, what we’re really talking about is relaxing and essentially dissolving the ego entirely so there is no experience of ‘you’ in the experience—you become one with the experience. But… what’s possible there is that we then access the nervous system and we see these very dramatic energetic releases and people often are physically reliving traumatic experiences and physically releasing the fight, flight, freeze response that may have happened or not happened.” [6:52]

“Trauma is complex and for some people it’s not that simple. For some people, they go through a six- to twelve-month process after 5-MeO-DMT that is really challenging.” [22:37]

“So [we’re] helping people… build sensitivity in their nervous system—reconnect with sensitivity and slowing things down and building more awareness and learning how to notice their emotions as sensations in the body before they become thought patterns.”  [32:00]

“I think one of the challenges in all of this is that people will lie to you to get to your experience because they’re desperate for the healing. And you have to be really careful about the conversations you have and asking open-ended questions and really listening to your intuition—and really being grounded in that.” [40:28] 

“What we’re doing here I would say there’s obviously a psychological component to it, but often that happens in the weeks and months afterwards. What’s happening here is a much more somatic experience and it can be very confusing and challenging for the mind of a person… you’ve paid all this money, you’ve prepared for weeks and months, you’ve been thinking about it, you come have this experience… Right after the ceremony for some people, the thought is ‘what just happened?’ and ‘did anything happen?’ and ‘did it work?’ because there’s very rarely like an immediate insight on ‘here’s how you’re going to make your life better’—that’s not what comes out of this experience. What comes out of this experience is a dramatic shift in how your body feels and often people will report feeling emotionally lighter or that they lost ten pounds. It’s hard to explain, but the way peoples’ eyes light up the day after the ceremony is so different—like they often just look different coming in and leaving.” [42:56]

Links:

Enfold Website

Enfold on Instagram

Enfold on YouTube

Still In It: 5-MeO-DMT Stories

Previous episode: Psychedelic Therapy: Slow Down to Heal Faster with Sunny Strasburg, LMFT

Previous episode: Psychedelic Adjunct Series: Somatic Therapy with Jenna Valentine, DACM, LAc

Previous episode: Ketamine-Assisted Psychotherapy for Accelerated Growth with Nick Brüss, EdD, LMFT

Previous episode: When *Not* to Proceed with a Planned Psychedelic Journey with Rick Barnett, PsyD

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Sunny Strasburg joins to open the conversation of leveraging lower doses of psychedelic substances for more effective healing. Sunny Strasburg, LMFT, a licensed psychotherapist, educator, and pioneering author, specializes in psychedelic therapies and training clinicians to be skilled and trauma-informed psychedelic therapists. As the founder and author of The Theradelic Approach, she equips clinicians with trauma-informed psychedelic-assisted therapy methods, blending IFS, EMDR, archetypal psychology, trauma-informed care, and her extensive experience.

In this conversation, Sunny shares insights drawn from Internal Family Systems (IFS) and explores how these perspectives can help inspire more effective psychedelic work, especially with lower doses. She emphasizes the importance of adequate preparation and not over-valorizing intense psychedelic experiences, noting that these therapies themselves can be traumatic if not handled with care. Sunny also discusses how one’s own internal protectors have adaptive rolls and display a lot of compassionate intelligence, so even though these parts may initially provide a barrier to deep trauma work, it is important for therapists to work collaboratively with these parts of a client’s psyche. In closing she talks about how to better set reasonable expectations in group psychedelic therapy and retreat settings, where integration can easily turn into a competition of who had the most intense experience, with things like ego dissolution becoming the barometer for healing. 

In this episode you'll hear:

• How “protector systems” and “rubber band effects” manifest in high-dose psychedelic therapy sessions

• Uncovering previously unknown traumas during psychedelic therapies and how therapists can be better prepared for this situation

• How therapists can skillfully work with symbolic material that arises in psychedelic journeys 

• The importance of slowing down and letting the client guide the pace when addressing serious traumas in particular

• Differences between ketamine, MDMA, and the classic psychedelics in terms of effects on the fear center of the brain

• Leveraging critical learning periods in therapy to reprocess traumatic memories

Quotes:

“Being a trauma therapist, you have to be skilled enough to know what is symbolic in a psychedelic journey, what’s a literal memory… You don’t want to do any kind of leading or prompting the client to fill in anything or directing them to anything—you’re really tracking where they are and letting them uncover their own path. Again, at the speed in which their protector system is ready for that.” [22:43]

“These parts want people to remember. They want to heal, they want to let their stories be told. And so our job as therapists is to clear the clutter so we can really hear the system and trust the system. The system knows.” [28:02]

“Trauma is like a sliver that’s buried in the arm—like in the deep skin of your arm and it’s got an infection around it. And all of your coping mechanisms, all of your protectors (using IFS language), is like building a giant layer of scar tissue on top of that. And you could just go through life with that, and you could just put lotion on the top of that scar and just try to make it look pretty—and that’s okay. But you could go in and surgically remove the sliver that’s been offending your system the whole time. And once you remove that sliver, you will start to heal—your arm will heal, it won’t have an infection anymore, right? But removing that sliver hurts. It’s painful. It’s a process. But you don’t have to deal with that sliver anymore. And that’s kind of how I imagine going through trauma work.” [31:08]

“I’ve had clients that I’ve worked with using EMDR, IFS for years, we’ve made some progress, but then we get ketamine on board and it’s totally helped them and amplified the benefit.” [35:13]

“Trust your protector system. Slow down. I promise, if you slow down and really get curious about what your protectors need, you will go so much further with these medicines. It really is not a race. It’s slow and steady, and you’re going to be able to get more work done.” [40:23]

Links:

Sunny’s website

Sunny on LinkedIn

Sunny on Instagram

Previous episode: Ketamine-Assisted Psychotherapy for Accelerated Growth with Nick Brüss, EdD, LMFT

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Dr. Hans Eriksson joins to discuss the potential of non-dissociative ketamine. Dr. Eriksson, Chief Medical Officer at HMNC Brain Health, is a highly respected drug developer and clinical psychiatrist with over 20 years of pharmaceutical experience. Prior to HMNC Brain Health, Dr. Eriksson served as Chief Medical Officer at COMPASS Pathways and previously as Senior Director of Clinical Research at Lundbeck and Medical Science Director at AstraZeneca.

In this conversation, Dr. Eriksson shares what inspired him to move from clinical practice to drug development, and why he sees so much potential in developing non-dissociative forms of ketamine. He discusses the ways the dissociative effects of ketamine decrease the accessibility of this treatment due to the fact that these changes in perception are undesirable for a significant portion of patients. Dr. Eriksson also shares results from preliminary studies of non-dissociative ketamine which showed efficacy in inducing anti-depressant effects. In closing, Dr. Eriksson discusses why he thinks the experiential element of the classical psychedelics play an important role in their efficacy as mental health treatments, but why this might not be the case when it comes to ketamine. 

In this episode you'll hear:

• The history of ketamine

• The pharmacology of ketamine’s dissociative effect

• The relationship between ketamine dose and antidepressant effect 

• The possibility of bladder issues and addiction with ketamine and whether non-dissociative forms of ketamine would also have these potentials

• How Dr. Eriksson thinks about combining psychotherapy with ketamine treatments

Quotes:

“We are aiming for a similar exposure to the drug as you achieve with, for instance, an intravenous administration, but we are achieving a much lower peak concentration, maximum concentration of the compound. So that is one of the characteristics of our formulation.” [10:58]

“Our view is that it's probably better to try to use the metabolism in the body as a tool to achieve very low exposure to ketamine but high exposure to the downstream metabolites.” [23:19]

Links:

Dr. Eriksson on LinkedIn

HMNC Brain Health on LinkedIn

HMNC Brain Health website

Previous episode: Potential Benefits of Non-Hallucinogenic Psychedelics with Kurt Rasmussen, PhD

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Chandra Khalifian, PhD joins to explore ketamine-assisted couples therapy. Dr. Chandra Khalifian is a clinical psychologist, researcher, educator and Co-CEO of Enamory, a clinic and community focused on providing expansive relationship education and therapy including psychedelic-assisted couple-therapy.

In this conversation Dr. Khalifian explores the intricacies of ketamine-assisted couples therapy, sharing why she thinks psychedelics, and ketamine in particular, could be a good fit for couples therapy. She discusses the various contexts where ketamine-assisted therapy may be a good fit for couples pursuing therapy, the therapeutic modalities well-suited to this work, and the different dosing and administration routes of ketamine. In closing, Dr. Khalifian explores situations where couples may be better suited to pursuing this therapy individually and also contexts where ketamine-assisted couples therapy would not be an appropriate intervention.

In this episode you'll hear:

• How Dr. Khalifian got involved in couples therapy

• The various models of ketamine-assisted couples therapy, and how to decide what is most appropriate

• The importance of preparation and integration

• How to navigate the two people in the couple having very different ketamine experiences

• When Dr. Khalifian uses intramuscular ketamine infusions versus ketamine lozenges

• Why Dr. Khalifian leans towards using third-wave cognitive behavioral therapy for ketamine-assisted therapy

• The tendency for people to make major relationship decisions following intense psychedelic experiences

Quotes:

“Ketamine is great because—in the same way with individuals—with couples it’s going to pull us out of that pattern so that we can then see the pattern and talk about the pattern from this observer perspective rather than being stuck in the ‘it’s me versus you’ we can look at it together and the couple can say ‘ah, there’s that thing that we do when we feel distressed, and now we can work together on that thing since we can see it from a little more distance.’” [4:43]

“Similar to MDMA, people are less likely to express criticisms in a hurtful way and less likely to receive constructive criticism and be defensive [during ketamine therapy].”  [9:05]

“I had one couple [as patients for ketamine therapy] that the partner was like ‘I just felt this liquid compassion. I finally understood why she was engaging in these behaviors. And so everything made sense and I was able to talk about it in a different way.’” [17:49] 

Links:

Enamory website

Enamory on Instagram

Previous episode: MDMA-Assisted Couples Therapy with Kayla Knopp, PhD

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Dr. Evan Cole Lewis joins to explore the topic of psychedelics and seizure disorders. Dr. Lewis is a Canadian Neurologist and holds an appointment as Assistant Professor in the Department of Paediatrics at the University of Toronto. He has special interest in the treatment of neurologic disorders, including functional seizures, with psychedelic therapies.

In this conversation, Dr. Lewis shares his expertise on a number of topics at the intersection of psychedelics and seizure disorders. He discusses the neurology behind psychedelics and functional neurological disorders more broadly, explaining why he thinks this is a very promising area of research. He explains that currently very little is known about the topic of psychedelics and seizure disorders, as almost all studies have had epilepsy as an absolute contraindication, leaving researchers with only case reports. However, there are some promising indications in the preclinical data which warrant further investigation. In closing, Dr. Lewis sheds light on potential seizure risks resulting from interactions between psychedelics and other medications. 

In this episode you'll hear:

• The different between epileptic seizures and functional seizures

• How Dr. Lewis started exploring the topic of psychedelics and functional seizures

• Why Dr. Lewis thinks psychedelic science has the potential to rebuild bridges between neurology and psychiatry

• Dr. Lewis’ experiences treating epileptic patients with ketamine

• The potential for co-administered lithium and psychedelics to cause seizures

Quotes:

“I tell people psychedelics are brain network medicine—they kind of dissolve those networks. If the thinking is that FND [Functional Neurological Disorder] is due to dysfunctional connection or hyperconnectivity in certain networks, what we have to do is we have to repair those networks, but first we have to take them apart and build them back up.” [11:03]

“Regardless, even if there isn’t even a condition in which psychedelics are utilized in neurology, we need the neurologists to be able to indicate that these patients are safe—or at least do the work and be involved in the clinical team.” [21:05]

“Things like drug interactions we pick up with psychedelics again are going to be a big piece of the puzzle that needs to be answered going forward.” [29:17]

Links:

Dr. Lewis on LinkedIn

Dr. Lewis on YouTube 

Case report: Improvement in refractory functional seizures, depression, and quality of life with by Dr. Lewis et al.

Psychedelics, epilepsy, and seizures: a review by Dr. Lewis et al.

Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review by Kelan Thomas, Benjamin Malcolm, et al.

ketamine-assisted therapy

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Dr. Jenna Valentine joins to explore the intersection of psychedelics and somatic therapy. Dr. Valentine is a doctor of Chinese Medicine who incorporates both functional medicine and somatic experiencing within her practice to help achieve optimal wellness.

In this conversation, Dr. Valentine introduces somatic therapy, drawing parallels to psychedelic work and exploring how this modality may support more healthy and holistic psychedelic experiences. She explains how somatic therapy proceeds by tuning into the body, with therapists helping to guide clients’ awareness of the intelligence in their bodies.

Dr. Valentine emphasizes the importance of not forcing things in somatic work - with gentler, slower practices often being best to align with health. In closing, she outlines how somatic therapy can be used for preparation and integration of a psychedelic experience, and also explores the possibilities of somatic modalities being used during psychedelic therapy. 

In this episode you'll hear:

• The different forms of somatic therapy

• The overemphasis on the mind in our culture

• Why there aren’t contraindications for somatic therapy

• Somatic therapy as a modality for working with patients diagnosed with biploar disorder or schizophrenia

• The intersection of healing and re-learning to be playful

• The importance of “doing less”

• Why glorifying “heroic doses” of psychedelics can be counterproductive to healing

• Shadow work and somatic therapy

Quotes:

“There’s many different definitions of [somatic therapy] but the one I love the most is: guiding yourself back to your body as your primary resource.” [4:02]

“A lot of the work is making sure people learn that they don’t have to feel afraid of themselves—no part of you is ‘coming to get you’ … no part of you is trying to trick you or hurt you or surprise you. Sometimes I’ll describe it as I’m helping people guide themselves back to themselves and find a safe home there again.” [13:05]

“We have lost our relationship with discomfort, and a lot of this work is uncomfortable. And the work is being in the discomfort and building a larger capacity for being uncomfortable, and learning the difference between uncomfortable and unhelpful, because that’s not something we’re trained in.” [23:41]

“There’s learning that can happen in everything … The expectation is to have no expectation: we can have a loose intention, and then let the body lead.” [47:18]

Links:

Dr. Valentine on Instagram

Dr. Valentine’s website

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast Tommaso Barba joins to explore the topic of psychedelics for sexual functioning and intimacy. Tommaso is a PhD candidate at the Centre for Psychedelic Research at Imperial College London where his research is focused on understanding the potential role of psychedelic drugs for well-being. Tommaso authored the first paper on the effects of psychedelics on sexual functioning.

In this conversation, Tommaso shares results from the multiple studies into psychedelics and sexual functions he has been involved in. He reports that in both a trial comparing psilocybin and escitalopram and a survey of naturalistic psychedelic use, respondents reported positive impacts on sexual functioning following psychedelic experiences. He also speculates about aspects of the psychedelic experience that are interpreted as “erotic” in the midst of the altered state and the reported shifts to experiencing sexual connection as more “spiritual” following psychedelic experiences. In closing, Tommaso discusses the promise of psychedelic journeys for healthy couples and the difficulties of researching this topic since there is no clear pathology being addressed. 

In this episode you'll hear:

• How Tommaso got interested in the intersection of psychedelics and sexual functioning

• Why SRRIs often have side effects of inhibiting sexual function

• How psychedelic neuropharmacology may help explain improved sexual functioning following psychedelic experiences

• The upcoming studies exploring the effects of psychedelic journeys on couples who undergo the experience together

• The possible differences between MDMA and classic psychedelics in terms of mechanism and impact when it comes to effects on sexual function

Quotes:

“When we looked at the positive affect symptoms—like wellbeing, connectedness, ability to feel emotions, and so on… Psilocybin outperformed escitalopram. And given so, we were really curious to investigate further the sex lives of these patients, because an active sex life is a key component of people’s wellbeing, and a very overlooked one.” [7:34]

“What we found was that people treated with psilocybin reported improvements in sexual pleasure, in capacity to communicate sexual desires with their partner, in sexual arousal, sexual satisfaction, and similar components of sexual functioning, while people treated with escitalopram did not report any of these changes and tended to report deterioration in this aspect of functioning.” [11:10]

“[These psychedelic treatments may] work because it disentangles couples and its capable of individuating the two patients into the context of their relationship so that they start to develop a better identity in the context of the relationship instead of being completely fused into each other and not capable of really developing themselves and communicating their desires and what they want.” [31:15]

Links:

Tommaso on Twitter

Tommaso on LinkedIn

Imperial College Centre for Psychedelic Research online survey study: psychedelics and couples

Previous episode: Microdosing and the Placebo Effect with Balázs Szigeti, PhD

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast Kayla Knopp joins to explore the topic of MDMA-Assisted Couples Therapy. Dr. Kayla Knopp is a clinical psychologist and researcher specializing in non-traditional couples and relationships. She specializes in making couple therapies more inclusive, accessible, and effective, including MDMA- and ketamine-assisted couple therapy.

In this conversation, Dr. Knopp introduces MDMA-assisted couples therapy, discussing why this entactogen is a good fit for couples therapy. She discusses how MDMA helps couples explore issues by dissolving typical defensive boundaries and encouraging empathy. She emphasizes that not all couples may be a good fit for this therapy, however, and especially cautions against couples therapy in contexts of abuse where connecting with resources for safety and pursuing individual courses of therapy is more appropriate. In closing, Dr. Knopp discusses the importance of screening and the responsibility the psychedelic community has to ensure these substances are being used in safe and effective therapeutic contexts overseen by qualified and caring facilitators.

In this episode you'll hear:

• The history of MDMA-assisted couples therapy

• When couple therapy is and is not appropriate

• Integrating MDMA-assisted therapy with cognitive-behavioral conjoint therapy for PTSD

• Therapeutic modalities which may be well-suited to MDMA-assisted couples therapy

Quotes:

“[MDMA] does so many things that are facilitative of the primary goals of couples therapy, which are to reduce defensiveness, to increase the flexibility that we have in taking our partner’s perspective, increase the empathy and intimacy we feel with other people, increase the reward that we get from positive interpersonal interactions.” [4:33]

“When we treat relationship dysfunction, we know mental health often improves as a result of that and conversely, we also know that sometimes when we do mental health treatments, if we ignore the relational context that somebody is living in, we only give them part of what they need in order to fully heal psychiatrically. So, couple-based interventions for mental health disorders, including PTSD, are up-and-coming as a really effective way to address mental health concerns.” [8:14]

“MDMA tends to increase our window of tolerance for emotional experiences—it makes it safer and easier for us to remain in contact with feelings that might otherwise feel pretty overwhelming.” [23:48]

“I think there’s absolutely a lot of ego and a toxic guru model that can show up in psychedelic-assisted therapy that, as a community, as practitioners, as participants, we need to keep an eye out for and keep ourselves accountable as a community to make sure that we’re not giving folks a pass.” [31:17]

Links:

Dr. Knopp on Instagram

Enamory website

Enamory on Instagram

Previous episode: Avoiding the Traps of Psychedelic Self-Absorption with Adam Aronovich, PhD(c)

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast we discuss the topic of psychedelics and postpartum mood disorders. Melissa Whippo is a licensed psychotherapist who specializes in the intersection of women's health and psychedelics. She founded a non-profit, Deva Collective, which has fiscal sponsorship with MAPS, and is currently conducting research about perimenopause and microdosing San Pedro.

In this conversation, Melissa shares the details of existing research into psychedelic treatments for postpartum populations. She discusses the findings from her study on “The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women,” reporting that ketamine was not detected at all in breast milk twelve hours after dosing. She also shares information on parents’ intentional use of microdosing and what motivates them to take up this practice. In closing, Melissa discusses her upcoming research on microdosing San Pedro among perimenopausal populations and why she decided to focus on San Pedro for this study.

In this episode you'll hear:

• The early research into ketamine for postpartum depression and whether ketamine remains in breast milk

• The prevalence of mood concerns in the postpartum population

• Issues of access with ketamine treatments for new mothers

• Improvements in postpartum mood patients following ketamine treatments that Melissa has seen in her practice

• Hormone changes after giving birth and how this might relate to mood concerns

• Ketamine for postpartum pain

Quotes:

“The reason why ketamine and other psychedelics appeal to me more [than other treatments for postpartum depression], is it’s not a medicine you have to take every day and it’s not a medicine that’s going to cause a significant separation [with the newborn] like a hospital admission would.” [5:55]

“More SSRI—which is still considered safe by the medical profession—passes through the breastmilk than ketamine. Probably nanograms. And ketamine has such a short half-life in the system, particularly with the intramuscular route of administration, that twelve hours after dosing, the breast milk was completely clear.” [14:22]

“That’s what ketamine does so well—it gives people a different view of some of the things they’re really struggling with that they can’t quite break through. Some of these more recursive ruminations that seem to befall mothers quite a bit—and they’re usually pretty negative. But the medicine space gives them a different view.” [18:52]

Links:

Melissa’s study: The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and Metabolites

Melissa’s article in the Washington Post: Some moms are microdosing mushrooms for anxiety and depression

Melissa’s website

Deva Collective website 

Melissa on Instagram

Plant Parenthood website

Previous episode: Psychedelics and Women’s Health with Allison Feduccia, PhD

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Hannah Raine-Smith and Jocelyn Rose join to discuss the psychedelic assisted EMDR therapy. Hannah is an integrative psychotherapist and independent researcher specializing in psychedelic integration using EMDR therapy. Jocelyn is a research therapist working on psychedelic clinical trials. She also works in private practice, and has a special interest in exploring the unfolding potential of EMDR as a scalable, trauma focused psychedelic assisted therapy.

In this conversation, Hannah and Jocelyn introduce the basics of eye movement desensitization and reprocessing (EMDR) therapy and its possible utility in adjunct to psychedelic assisted therapies. They discuss the overlapping mechanisms between EMDR and psychedelic therapies, with both engaging the serotonin 5-HT2 system and promoting neuroplasticity. Hannah and Jocelyn explain their excitement around integrating EMDR with psychedelic therapy, stressing that this may make these treatments more accessible for the patients who could benefit most from psychedelic therapy. In closing, the researchers call for additional investigation of the intersection of psychedelic therapy and EMDR and invite collaboration from anyone else exploring these promising treatments. 

You can contact Hannah and Jocelyn at info@bridgetothematrix.com

In this episode you'll hear:

• How EMDR works to help people process traumatic memories

• Similar neurological effects of psychedelic therapies and EMDR

• Understanding the adaptive information processing (AIP) framework

• Hannah and Jocelyn’s novel hypothesis for the basis of hallucinogen persisting perception disorder (HPPD)

• Using EMDR as an integration therapy for past psychedelic experiences

• Making psychedelic treatments more accessible and inclusive

Quotes:

“Like with indigenous shamanic practices, EMDR uses simple rhythms to alter consciousness. So EMDR is like an ancient healing mechanism that’s been adapted to treat the modern soul.” [4:56]

“When we reprocess these memories using bilateral stimulation of the brain, you start thinking and feeling differently about the same events. So trauma therapy isn’t about changing the past, it’s about how you think and feel about those experiences.” [5:26]

“Some of the resistance that would normally be present in an EMDR session is diminished when someone has had a recent psychedelic experience.” [12:02]

“Research has shown that EMDR taps into the same mechanisms as REM [sleep]. It’s like adding the healing benefits of dreaming whilst on psychedelics but being more in control of what gets reprocessed.” [14:42]

“The people who are most likely to have adverse drug reactions to psychedelics—whether that’s HPPD or tolerance—tend to be the people who also have adverse childhood experiences or have traumatic complexity in their biographical content. And so we recognize that there’s a need for trauma-focused psychedelic treatments if we’re going to make these treatments available to the people who need them most and make them scalable—and we think EMDR is a good enough fit for that work to happen.” [25:46]

Links:

Hannah and Jocelyn’s article: “Psychedelic-assisted EMDR therapy (PsyA-EMDR): A memory consolidation approach to psychedelic healing”

Bridge to the Matrix: A Memory Consolidation Approach to Psychedelic Healing website

Hannah on LinkedIn

Jocelyn on LinkedIn

Previous episode: Ketamine-Assisted Psychotherapy for Accelerated Growth with Nick Brüss, EdD, LMFT 

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Steven Radowitz, MD joins to discuss the state of the research into ketamine treatments for PTSD. Dr. Steven Radowitz is the Chief Medical Officer and Co-Founder, Nushama. He believes psychedelic medicine’s framework of neuroscience, mystical experience, and integration therapy is the future of mental wellness, and current solutions often fall short, treating symptoms without addressing underlying issues. Dr. Radowitz and the Nushama team have administered thousands of ketamine journeys for mood disorders and are known to be best-in-class and among the most experienced globally.

In this conversation, Dr. Radowitz shares the journey of his career in medicine and how he got involved in the treatment of mood disorders with ketamine. He discusses the way he works with patients to determine the best dosing of ketamine for their unique therapeutic needs and the way dosage intersects with the durability of the changes. Dr. Radowitz emphasizes how ketamine promotes neuroplasticity, which allows patients with PTSD to open a critical response window when confronted with triggers and re-code memories of trauma. In closing, Dr. Radowitz discusses the importance of integration and highlights the way psychedelic therapies empower patients to be their own healers.

In this episode you'll hear:

• Using both psycholytic and psychedelic doses of ketamine and how therapeutic approach differs between the two

• Stories of transformation from Dr. Radowitz’s ketamine practice

• The practices Dr. Radowitz recommends for patients following ketamine infusions

• How Dr. Radowitz uses music in his ketamine practice

Quotes:

“As much as we segregate all these mood disorders into separate disease entities… there’s actually a common seed for them all—there’s just different manifestations. But I say about 95% of the people who come in here [for ketamine treatments] have some type of trauma.” [4:56]

“The dose doesn’t always correlate with the experience—it usually doesn’t. I can give people the same dose, with the same music, same everything, and they'll have completely different experiences each time.” [13:23]

“What we do here is to create a medically safe and an emotionally safe environment for [patients]. But the medicine is them—they’re the therapists in the end. … I want them to realize it’s all coming from them. They have everything they need within themselves to heal.” [32:15]

Links:

Nushama website

Nushama on LinkedIn

Nushama on Instagram

Nushama on Facebook

Nushama on TikTok

Dr. Radowitz on Linkedin

The Untethered Soul: The Journey Beyond Yourself by Michael A. Singer

Letting Go: The Pathway of Surrender by David R. Hawkins

Psychedelic Medicine Association

Porangui

In this episode of the Psychedelic Medicine Podcast, Rick Strassman, MD joins to discuss the topic of endogenous DMT. Dr. Strassman is adjunct associate professor of psychiatry at the University of New Mexico in Albuquerque and author of DMT: The Spirit Molecule and The Psychedelic Handbook. His DMT and psilocybin studies in the early 1990s initiated the renewal of human research with psychedelics in the U.S.

In this conversation, Dr. Strassman discusses the finer details of DMT, from endogenous production in humans and animals, to visionary experiences and theological implications. Dr. Strassman also covers the research that's been done regarding endogenous DMT, clarifying what we do and don’t know about the role of the pineal gland and how this might relate to what is reported during near-death experiences. He also discusses the personal and relational quality of psychedelic experiences induced by DMT, mentioning that unitive mystical experiences were actually rare in the trials he conducted, with more experiences having a personal quality, drawing upon the life experiences and interests of the participants. In closing, Dr. Strassman shares his thoughts on the origins of the visions that many report during DMT use. 

In this episode you'll hear:

• The overlap between psychedelic experiences and meditation techniques

• The relationship between fear, self-awareness, and difficult DMT experiences

• The placebo effect and psychedelic research

• Dr. Strassman’s thoughts on non-hallucinogenic psychedelics

• DMT as a possible treatment for strokes to prevent damage and speed recovery

• Effects of microdosing in animals and humans

Quotes:

“I think the best term for these compounds is psychedelic, which means mind manifesting or mind disclosing, because only one of our fifty-five or so normal volunteers had what one might call a mystical unitive state. … Everybody basically had an experience that was totally dependent on them. It was not inherent in the drug.” [9:45]

“You could still speculate that to the extent that non-drug states resemble those brought on by giving DMT… that DMT plays a role in the production of those states. But the data aren't there yet. That's why we need more people doing this research.” [24:16]

“If psychedelics are super placebos and if we have a psychedelic drug in our brain, it's attempting to speculate that normally the placebo effect could be mediated by endogenous DMT.” [27:42]

“If you starve neurons of oxygen they start dying, but if you add DMT they survive much longer. So there seems to be some neuroprotective effect of DMT on ischemic damage to neurons, at least in the test tube.” [32:27]

Links:

Dr. Strassman’s website

The Psychedelic Handbook by Dr. Strassman

DMT: The Spirit Molecule by Dr. Strassman

DMT and the Soul of Prophecy: A New Science of Spiritual Revelation in the Hebrew Bible by Dr. Strassman

Dr. Strassman on Facebook
Previous episode: Exploring DMT Entities with Matthew Johnson, PhD

Psychedelic Medicine Association

Porangui